Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/37942| Title: | Safety of Alemtuzumab in Patients with Multiple Sclerosis: Interim Results of a Post-Authorization Safety Study (PASS) | Authors: | Montalban, X. VAN WIJMEERSCH, Bart Gobbi, C. Robertson, N. Klotz, L. Achiron, A. Lee, A. Eichau, S. Vecsei, L. Benzerdjeb, H. Rodrigues, A. Jurgensen, S. Chirieac, M. Comi, G. |
Issue Date: | 2022 | Publisher: | WILEY | Source: | European journal of neurology (Print), 29 , p. 288 | Document URI: | http://hdl.handle.net/1942/37942 | ISSN: | 1351-5101 | e-ISSN: | 1468-1331 | ISI #: | 000815254001153 | Category: | M | Type: | Journal Contribution |
| Appears in Collections: | Research publications |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| 120.pdf Restricted Access | Published version | 224.18 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.